Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 34 of 34 results for secukinumab

  1. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    Discontinued Reference number: GID-TA10598

    Technology appraisal guidance
    Discontinued

  2. Spesolimab for treating generalised pustular psoriasis flares (TA1070)

    Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.

    Technology appraisal guidance
    Published
    18 June 2025
    View recommendations

    Sections for TA1070

  3. Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]

    In development Reference number: GID-TA11761 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA419